Standard BioTools Sees Total Revenue Of $100M-$105M For FY23; Expects Non-GAAP Gross Margin Of ~60%
Portfolio Pulse from Benzinga Newsdesk
Standard BioTools has projected its total revenue for FY23 to be between $100M and $105M. The company also anticipates a non-GAAP gross margin of approximately 60%.
November 08, 2023 | 12:29 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Standard BioTools' revenue forecast for FY23 could potentially impact LAB, if they have a business relationship.
The news does not provide specific details about the relationship between Standard BioTools and LAB. Therefore, the impact is uncertain and depends on the nature of their business relationship.
CONFIDENCE 50
IMPORTANCE 50
RELEVANCE 50